Kura Oncology Reports Pricing Of $100M Public Offering Of Common Stock And Pre-funded Warrants
Portfolio Pulse from Benzinga Newsdesk
Kura Oncology announced the pricing of its $100M public offering, selling 5,660,871 shares of common stock at $11.50 per share and pre-funded warrants to purchase 3,034,782 shares at $11.4999 per warrant.
June 14, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kura Oncology's $100M public offering may lead to short-term dilution of existing shares, potentially impacting the stock price.
Kura Oncology's public offering of common stock and pre-funded warrants will increase the number of outstanding shares, which may lead to short-term dilution of existing shares. This could result in a negative impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100